Jerzak P, Konieczny A, Sroka M, Lis L, Podgórski P, Witkiewicz W, Hruby Z

Language: English
References: 12
Page: 23-29
PDF size: 305.74 Kb.

ABSTRACT

Background: Primary focal and segmental glomerulosclerosis progresses to end-stage renal disease in every other patient, and therefore determinants of its long-term outcome have been extensively studied. Immediate response to treatment has been regarded as a positive prognostic predictor and short-term manifestation of the disease could affect its determinants. Therefore, we have sought to assess the early clinical course of primary adult focal and segmental glomerulosclerosis and analyze its prognostic factors. Methods: We have retrospectively assessed clinical course of primary focal and segmental glomerulosclerosis (“not otherwise specified” histological variant) in 84 adults. Renal function was expressed as serum creatinine concentration and equilibrated glomerular filtration rate (MDRD equation). Proteinuria was expressed as protein to urinary creatinine ratio, assessed in the morning voiding sample. The evaluation of these parameters was performed every 3 months after diagnosis. Statistical analysis was achieved using package Statistica. Results: As result of treatment, complete remission of proteinuria, was attained in 30 subjects (35.7%), partial remission in 37 persons (44%), whereas in 17 patients protein excretion rate remained unchanged (20.2%). The severity of glomerular injury, at initial presentation of the disease, correlated with its early (12 months) outcome: patients attaining early complete remission have had the lowest initial proteinuria, higher serum albumin and total protein concentrations than those who have failed to achieve remission. Pharmacotherapy with prednisone, but not with calcineurin inhibitors or mycophenolate mofetil was demonstrated to significantly affect achievement of remission. Conclusions: Early remission of proteinuria in response to treatment is feasible in 44% of patients with primary focal and segmental glomerulosclerosis, it is best achieved in subjects presenting with mild glomerular injury, and in patients treated with prednisone. Higher serum albumin and total protein concentrations predict better response to induction of remission.

REFERENCES

1. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: epidemiology of kidneydisease in the United States. Am J Kidney Dis. 2019;73(3Suppl. 1):A7-A8. doi: 10.1053/j.ajkd.2019.01.001.

2. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focalsegmental glomerulosclerosis in nephrotic adults:presentation, prognosis, and response to therapy of thehistologic variants. J Am Soc Nephrol. 2004;15(8):2169-77. doi: 10.1097/01.ASN.0000135051.62500.97

3. D‘Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologicclassification of focal segmental glomerulosclerosis: aworking proposal. Am J Kidney Dis. 2004;43(2):368-82. doi: 10.1053/j.ajkd.2003.10.024.

4. Swarnalatha G, Ram R, Ismal KM, Vali S, SahayM, Dakshinamurty KV. Focal and segmentalglomerulosclerosis: does prognosis vary with thevariants? Saudi J Kidney Dis Transpl. 2015;26(1):173-81. doi: 10.4103/1319-2442.148772.

5. Kim JS, Han BG, Choi SO, Cha SK. SecondaryFocal Segmental Glomerulosclerosis: From PodocyteInjury to Glomerulosclerosis. Biomed Res Int.2016;2016:1630365. doi: 10.1155/2016/1630365.

6. Beck L, Bomback AS, Choi MJ, Holzman LB, LangfordC, Mariani LH, et al. KDOQI US commentaryon the 2012 KDIGO clinical practice guideline forglomerulonephritis. Am J Kidney Dis. 2013;62(3):403-41. doi: 10.1053/j.ajkd.2013.06.002.

7. Silverstein DM, Craver R. Presenting features andshort-term outcome according to pathologic variant inchildhood primary focal segmental glomerulosclerosis.Clin J Am Soc Nephrol. 2007;2(4):700-7. doi: 10.2215/CJN.00230107.

8. Beer A, Mayer G, Kronbichler A. Treatment strategiesof adult primary focal segmental glomerulosclerosis:a systematic review focusing on the last twodecades. BioMed Res Int. 2016(3):4192578. doi:10.1155/2016/4192578.

9. Troyanov S, Wall CA, Miller JA, Scholey JW, CattranDC; Toronto Glomerulonephritis Registry Group.Focal and segmental glomerulosclerosis: definitionand relevance of a partial remission. J Am Soc Nephrol.2005;16(4):1061-8. doi: 10.1681/ASN.2004070593.

10. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, JennetteC, Falk RJ, et al. Treatment with Glucocorticoidsor Calcineurin Inhibitors in Primary FSGS. Clin JAm Soc Nephrol. 2016;11(3):386-94. doi: 10.2215/CJN.07110615.

11. Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y,et al. The Level of Serum Albumin Is Associatedwith Renal Prognosis in Patients with DiabeticNephropathy. J Diabetes Res. 2019;2019:7825804. doi:10.1155/2019/7825804.

12. Deegens JK, Assmann KJ, Steenbergen EJ, HilbrandsJB, Gerlag PGG, Jansen JLJ, et al. Idiopathic focalsegmental glomerulosclerosis: a favourable prognosis inuntreated patients? Neth J Med. 2005;63(10):393-8.